Idiopathic thrombocytopenic purpura is commonly treated with which class of medication as first-line therapy?

Idiopathic thrombocytopenic purpura is commonly treated with which class of medication as first-line therapy?

• A. Intravenous Immunoglobulin
• B. Platelet Transfusion
• C. Antibiotics
• D. Steroids

Answer: (D)

Immune thrombocytopenic purpura arises from autoantibody-mediated destruction of platelets. The first-line approach is to dampen this immune response, and corticosteroids do exactly that: they decrease autoantibody production and reduce spleen-mediated destruction of platelets, leading to a meaningful rise in platelet counts within days to a couple of weeks. A typical course includes prednisone around 1 mg/kg daily or a short, high-dose dexamethasone regimen, with many patients responding as the steroid is tapered. If the response is insufficient or relapse occurs during tapering, second-line options like splenectomy, rituximab, or thrombopoietin receptor agonists are considered. IVIG can rapidly raise platelets in the setting of active bleeding or before procedures, but it’s not first-line because steroids are simpler, effective, and more cost-efficient. Platelet transfusions are not usually helpful in ITP because the autoantibodies will destroy the transfused platelets, except in life-threatening bleeding where they’re used as part of urgent management.

Immune thrombocytopenic purpura arises from autoantibody-mediated destruction of platelets. The first-line approach is to dampen this immune response, and corticosteroids do exactly that: they decrease autoantibody production and reduce spleen-mediated destruction of platelets, leading to a meaningful rise in platelet counts within days to a couple of weeks. A typical course includes prednisone around 1 mg/kg daily or a short, high-dose dexamethasone regimen, with many patients responding as the steroid is tapered. If the response is insufficient or relapse occurs during tapering, second-line options like splenectomy, rituximab, or thrombopoietin receptor agonists are considered. IVIG can rapidly raise platelets in the setting of active bleeding or before procedures, but it’s not first-line because steroids are simpler, effective, and more cost-efficient. Platelet transfusions are not usually helpful in ITP because the autoantibodies will destroy the transfused platelets, except in life-threatening bleeding where they’re used as part of urgent management.